| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President & Chief R& D Officer | President & Chief Res & Dev Officer +1 more
1 company
Robert Coffin last filed a Form 4 in May 2024, as Director at REPL. Robert Coffin's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Robert Coffin a middling insider score of 61/100, based on 6 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +30.8%.
At the last filing, the largest reported position was 1,821,872 shares of REPL. The REPL filings lean toward selling, a net 738,361 shares.
Robert Coffin has 20 Form 4 filings on record from July 2018 to May 2024, all as Director at Replimune Group (REPL), 2018–2024.
The 29 reported transactions were 20 open-market sales, 6 option or other derivative awards and 3 stock awards.
Counted by filing, the open-market trades come to no purchases and 14 sales worth about $21.1M.
The largest open-market sale was 220,000 shares of REPL at an average $40.04 on December 22, 2020, about $8.8M.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from May 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 16, 2024 | REPL Replimune Group, Inc. | Director | Sell | 11,464 | $6.47 | $74,172.08 | -0.6% | +46.7% | +16.8% | |
| May 16, 2023 | REPL Replimune Group, Inc. | President & Chief R& D Officer | Sell | 7,861 | $18.05 | $141,891.05 | -0.4% | +6.5% | -63.2% | |
| May 16, 2022 | REPL Replimune Group, Inc. | President & Chief R& D Officer | Sell | 5,737 | $14.59 | $83,702.83 | -0.3% | +42.1% | +27.3% | |
| Jul 2, 2021 | REPL Replimune Group, Inc. | President & Chief R& D Officer | Sell | 7,810 | $40.04 | $312,712.40 | -0.4% | -25.0% | -53.5% | |
| Jun 29, 2021 | REPL Replimune Group, Inc. | President & Chief R& D Officer | Sell | 37,489 | $40.05 | $1,501,287.82 | -2.1% | -17.6% | -55.5% | |
| Jan 22, 2021 | REPL Replimune Group, Inc. | President & Chief R& D Officer | Sell | 60,000 | $44.43 | $2,665,973.36 | -3.3% | - | - | |
| Dec 22, 2020 | REPL Replimune Group, Inc. | President & Chief R& D Officer | Sell | 220,000 | $40.04 | $8,808,800.00 | -10.9% | - | - | |
| Jul 9, 2020 | REPL Replimune Group, Inc. | President & Chief R& D Officer | Sell | 169,750 | $22.13 | $3,757,295.00 | -7.7% | - | - | |
| Feb 20, 2020 | REPL Replimune Group, Inc. | President & Chief Res & Dev Officer | Sell | 24,250 | $17.04 | $413,220.00 | -1.1% | - | - | |
| Feb 12, 2020 | REPL Replimune Group, Inc. | President & Chief Res & Dev Officer | Sell | 48,500 | $17.04 | $826,197.50 | -2.1% | - | - |